Vivos Therapeutics, Inc. (NASDAQ:VVOS) Given Consensus Rating of “Hold” by Brokerages

Shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) have been given an average recommendation of “Hold” by the five analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $4.9167.

A number of analysts have recently weighed in on VVOS shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Wednesday, January 21st. Ascendiant Capital Markets dropped their price target on Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating for the company in a research note on Wednesday, December 3rd. HC Wainwright assumed coverage on shares of Vivos Therapeutics in a research note on Monday, November 17th. They set a “buy” rating and a $7.00 price objective on the stock. Finally, Zacks Research raised shares of Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, December 1st.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new stake in shares of Vivos Therapeutics in the 2nd quarter valued at $65,000. B. Riley Wealth Advisors Inc. acquired a new position in shares of Vivos Therapeutics during the 2nd quarter worth $220,000. Finally, Connective Capital Management LLC bought a new stake in shares of Vivos Therapeutics during the 3rd quarter worth $620,000. 26.35% of the stock is currently owned by institutional investors and hedge funds.

Vivos Therapeutics Stock Performance

Shares of NASDAQ:VVOS opened at $1.62 on Friday. The company’s 50 day moving average price is $2.05 and its two-hundred day moving average price is $3.14. Vivos Therapeutics has a 12-month low of $1.56 and a 12-month high of $7.95. The firm has a market cap of $15.29 million, a PE ratio of -0.92 and a beta of 6.89. The company has a quick ratio of 0.78, a current ratio of 0.78 and a debt-to-equity ratio of 3.31.

Vivos Therapeutics (NASDAQ:VVOS) last released its quarterly earnings results on Wednesday, November 19th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. The company had revenue of $6.78 million during the quarter, compared to the consensus estimate of $4.49 million. Vivos Therapeutics had a negative net margin of 98.77% and a negative return on equity of 351.28%. Equities research analysts predict that Vivos Therapeutics will post -1.79 earnings per share for the current year.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.